Sabinsa has received a Grant of Patent from the New Zealand Patent Office, which describes processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin.
NZ Patent No: 568652 “Commercial Process for Making Forskolin and its Derivatives” will be in force until February 2, 2027.
This most recent patent is #63 in Sabinsa’s sizeable worldwide Intellectual Property portfolio. Additionally, Sabinsa has over 50 pending patent applications worldwide. The company continues to demonstrate its commitment to keeping the spirit of innovation alive in the industry, through sustained intellectual property creation and protection efforts.
This patent furthers Sabinsa’s ability to protect their Intellectual Property as they make inroads into Oceania. The company recently received Product Information (PI) numbers for ForsLean® 10% and 20% from Australia’s TGA (Therapeutic Goods Administration), a division of the Australian Government Department of Health and Ageing, opening the way for ForsLean to enter the Australian market.